Engineering vasoactive protease sensors for brain-wide biomarker imaging

Summarise with VIRAT
Authors: M. Pethe, N. Jain, B. Sootha, Robert Ohlendorf
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Proteases like Fibroblast Activation Protein (FAP) and Matrix Metalloprotease 9 (MMP9) regulate neural plasticity, network remodeling, and blood-brain barrier integrity1,2. They are also implicated in neurodegeneration and tumors1,2. Yet their precise in vivo activity is difficult to measure. This project develops genetically encodable vasoactive sensors3,4 to map protease activity in the living mammalian brain using fMRI. The resulting vasoactive FAP sensor is tested in vitro and in vivo, potentially enabling in future minimally invasive mapping of protease function in health and disease. Methods: FAP sensor variants were designed and cloned into a mammalian expression vector and expressed in HEK293 Freestyle cells. The secreted sensor protein was purified from culture supernatant and characterized for sensor activity. For in vivo validation, adeno-associated virus (AAV) encoding the sensor was stereotaxically injected into the caudate putamen of Sprague-Dawley rats. Four weeks later, animals underwent cannula implantation and 14.1 T fMRI during intracranial FAP/PBS infusion using Echo-planar imaging (EPI). Imaging data were motion-corrected, coregistered to anatomical references, and spatially smoothed before voxel-wise percent signal change analysis, generating T2*-weighted activation maps overlaid on anatomical images. Results/Discussion: The vasoactive sensor consists of a blocking domain, protease recognition site, and vasoprobe; proteolytic cleavage sets the vasoprobe free to bind vascular receptors inducing vasodilation and hemodynamic signals detectable by fMRI (Fig.1A). Sensor variants were screened in vitro using a cell-based luminescence platform expressing vasoprobe-specific receptors (Fig.1B). The FAP sensor showed concentration-dependent activation by FAP with a half-maximal effective concentration (EC50) in nanomolar range (Fig.1C), and high specificity for FAP over other proteases (Fig.1D). In vivo, rats injected with FAP sensor AAV (FAP AAV) show robust fMRI signal changes upon stimulation with FAP compared to controls (Fig.2A,B,C). Histology confirmed that fMRI signals coincide with AAV-mediated sensor expression (Fig.2C). Based on the FAP sensor design, we also developed a genetically encodable MMP9 sensor highlighting the versatility of our sensor design to target various proteases (Fig.2D). Conclusion: This work validates vasoactive protease sensors as a tool for minimally invasive, brain-wide imaging of enzymatic activity. The FAP sensor shows high specificity, the nanomolar detection and robust in vivo fMRI responses. Further, the MMP9 sensor demonstrates design versatility. Together, these sensors can enable spatiotemporal mapping of protease function relevant to plasticity, extracellular matrix remodeling, inflammation, and disease.

Fields of Study & Subjects

Advanced Fluorescence Microscopy Techniques Peptidase Inhibition and Analysis Protease and Inhibitor Mechanisms

Publication details

Journal / source
MPG.PuRe (Max Planck Society)
Publication date
1 January 2026
Language
EN